News - Biotechnology, Biotie Therapies

Filter

Popular Filters

Biotie to regain global rights to tozadenant from UCB

Biotie to regain global rights to tozadenant from UCB

26-03-2014

Finland-based Biotie Therapies says that partner Belgium-based drugmaker, following a portfolio review,…

BiotechnologyBiotie TherapiesLicensingNeurologicaltozadenantUCB

Biotie invests in Alzheimer’s drug SYN120 as it drops epilepsy pathway

Biotie invests in Alzheimer’s drug SYN120 as it drops epilepsy pathway

11-03-2014

Finland-based Biotie Therapies (Nasdaq OMX: BTH1V), which is focused on neurodegenerative and psychiatric…

BiotechnologyBiotie TherapiesFinancialFinlandHealthcareNeurologicalNRL-1SYN120

Lundbeck and Otsuka partner on Biotie’s nalmefene in Japan

Lundbeck and Otsuka partner on Biotie’s nalmefene in Japan

31-10-2013

Biotie Therapies says that its partner, Lundbeck has expanded its existing alliance with Otsuka Pharmaceutical…

Asia-PacificBiotechnologyBiotie TherapiesLicensingLundbeckMarkets & MarketingnalmefeneNeurologicalSelincro

Biotie buys option to acquire Neurelis, and opportunity for epilepsy candidate

04-06-2013

Finland-based biotech firm Biotie Therapies (Nasdaq-OMX; BTH1V) says that it has obtained an exclusive…

BiotechnologyBiotie TherapiesMergers & AcquisitionsNeurelisNeurologicalNRL-1Pharmaceutical

Lundbeck takes 5% stake in Biotie; amends Selincro licensing deal

07-09-2012

Danish CNS drug specialist Lundbeck A/S (LUND: DC) said this morning that it has made an investment of…

BiotechnologyBiotie TherapiesFinancialLicensingLundbeckMergers & AcquisitionsNeurologicalPharmaceuticalSelincro

Biotie assets available for partnering; update on tozadenant

08-07-2012

Finland-based biotech firm Biotie Therapies' (OMX: BTH1V) retention of SYN120 rights after Roche decided…

BiotechnologyBiotie TherapiesFinancialLicensingLundbeckNeurologicalResearchSelincroSYN120tozadenantUCB

Benefits of Biotie’s 45 million-euro buy of Newron assessed by Edison Research

16-10-2011

Finland-based Biotie Therapies’ (OMX: BTH1V) proposed c 45 million-euro all-stock merger with Italian…

BiotechnologyBiotie TherapiesMergers & AcquisitionsNeurologicalNewron PharmaPharmaceuticalResearch

Biotie to buy Newron for 45 million euros, creating a European leader in CNS drug development

27-09-2011

In a second acquisition this year, Finland-based biotech company Biotie Therapies (OMX: BTH1V) has entered…

BiotechnologyBiotie TherapiesMergers & AcquisitionsNeurologicalNewron PharmaPharmaceutical

Back to top